# China NMPA Drug Inspection - Anhui Hongxin Pharmaceutical Development Co., Ltd. - Salt plantain

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-hongxin-pharmaceutical-development-co-ltd/76364d07-51be-4c9d-bac7-5f7e4e53c292
Source feed: China

> China NMPA drug inspection for Anhui Hongxin Pharmaceutical Development Co., Ltd. published September 29, 2020. Drug: Salt plantain. The Shaanxi Provincial Drug Administration published its ninth Drug Quality Bulletin of 2020 on September 29, 2020, foll

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shaanxi Province Drug Quality Bulletin (Issue 9, 2020, Serial No. 19)
- Company Name: Anhui Hongxin Pharmaceutical Development Co., Ltd.
- Publication Date: 2020-09-29
- Drug Name: Salt plantain
- Inspection Finding: The product does not meet the requirements; the non-compliant item is [property].
- Action Taken: The relevant municipal (county, district) drug regulatory authorities have taken necessary control measures and are investigating and handling the matter in accordance with relevant laws and regulations.
- Summary: The Shaanxi Provincial Drug Administration published its ninth Drug Quality Bulletin of 2020 on September 29, 2020, following a series of province-wide sampling inspections. The report identifies five specific batches of drugs that failed to meet quality standards. The non-compliant manufacturers include Anhui Hongxin Pharmaceutical Development Co., Ltd., Anhui Bozhou Qiancao Guoyao Co., Ltd., Ningxian Kangshengyuan Pharmaceutical Co., Ltd., Qingyang Yixiang Pharmaceutical Co., Ltd., and Shanxi Taiyuan Pharmaceutical Co., Ltd. The primary violations cited involve failures in physical appearance (characteristics), content determination, and general inspection parameters. All products were evaluated against the 2015 Edition of the Chinese Pharmacopoeia (Parts I and II). In response to these findings, the Shaanxi Provincial Drug Administration has instructed municipal and county-level regulatory bodies to implement immediate control measures on the affected batches. Furthermore, the involved units are currently under investigation, with legal and administrative actions being pursued in accordance with national drug safety laws to ensure public medication safety and industry compliance.

Company: https://www.globalkeysolutions.net/companies/anhui-hongxin-pharmaceutical-development-co-ltd/33bf883c-f9e4-4cd3-aa2f-92030d347daf